Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 1996

View Archived Issues

Lilly describes heterocyclic tachykinin antagonists

Faulding's Kadian approved by FDA

ProCyte seeks FDA marketing clearance for OsmoCyte

OncorPharm acquires rights to dithymidine-based products

Erythromycin derivatives useful for infection treatment

U-94901: A powerful antibacterial agent from Pharmacia & Upjohn

Novel antibacterial agents from Pharmacia & Upjohn

Vion issued U.S. patent regarding hepatitis B treatment

Abbott presents HIV RNA-reducing drug combinations

Zerit reaches Canadian market

New formulaton of Videx launched in Canada

3TC/AZT combination phase II/III trial results published

Acemannan ineffective on surrogate markers

Positive efficacy/safety profile for liposomal formulation of DaunoXome

Whole-body extracorporeal hyperthermia trials enter phase II

AIDS Research Highlights (July 7-12, Vancouver)

Artemether as effective as quinine in malaria studies

COX-2 inhibitors for inflammation and/or pain from Roche

Bayer discloses matrix metalloproteinase inhibitors

Antiinflammatory bone resorption inhibitors from Takeda

SB-210313: A potent LPS-TNF production inhibitor

Ciba-Geigy identifies antiinflammation agents

Immunosuppressive and antiinflammatory agents from Italfarmaco

Sankyo reveals potential immunosupressants

GT32-B: a novel antibacterial/antitumor immunosuppresant

TCV-309: Potential agent for transplantation of ischemically injured kidney

Positive safety, efficacy profile of HMG-CoA reductase inhibitors in hyperlipidemia treatment

ICOS issued U.S. patent relating to ICAM-3

Yoshitomi and Yamasa Shoyu out-license DMDC

Taxotere approved in eight countries for two indications

Arimidex approved for Austrian, German and Italian markets

Multikine enters Canadian phase I/II trial

Protein tyrosine kinase inhibitors from Warner-Lambert

PD-158780: A potent and selective EGF tyrosine kinase inhibitor

Protein farnesyltransferase inhibitor in Warner-Lambert's compound library

Potent tyrosine kinase inhibitors derived from PD-089828

Arizona Board of Regents reports antitumor pentapeptides

Interim phase I/IIa results for Genta's G-3139 as non-Hodgkin's lymphoma agent

Canji issued two patents for p53 gene therapy for cancer

Multidrug resistance modifiers from Vertex

IB-367: IntraBiotic's first drug candidate

Non-steroidal compounds for postmenopausal disorders described by Lilly

Cathepsin B and L inhibitors in Fujisawa's pipeline

(+)-Sch-58053: Schering-Plough's cholesterol absorption inhibitor

Pfizer and Warner-Lambert sign atorvastatin agreement

Aryloxypropanolamine beta3-adrenoceptor agnoists from Bristol-Myers Squibb

Results of fat accumulation/PAI-1 levels relationship study disclosed

Pharmacia & Upjohn terminates Hemopure codevelopment agreement

Optro enters U.S./Canadian phase II trials

FDA approves Nicotrol for OTC marketing

Biphenyl iodinated derivatives for X-ray diagnosis from Bracco

8-epi-PGF2alpha used in antioxidant measurement test

ChemTrak's Helicobacter pylori rapid test receives FDA approval

Cel-Sci and University of Maryland awarded HIV-1p17 diagnostic development grant

Cortecs and Exocell codevelop diabetes management test

T Cell Sciences awarded U.S. patent covering TRAx products

CEA-Scan cleared for market by FDA

AMDL seeks FDA approval for PyloriProbe

Medtronic's HemoStatus approved by FDA

Melatonin effective for jet lag/shift lag

Potential CNS disorders treatment from Janssen

Potent, selective mGluR2 agonist from Lilly

Pharmacia & Upjohn's dopamine D4 receptor ligands

Lundbeck's Serdolect reaches first market

Arris issued U.S. patent for drug design technology

Collaboration on signal transduction inhibitor drug discovery announced

Phytera and Tsumura Juntendo collaborate in rheumatoid arthritis/allergy R&D

Heliosynthese and Scotia receive EEC Eureka award for microalgae research

Oculex receives grants for ocular drug delivery research

SmithKline Beecham/Human Genome Sciences human genome collaboration no longer exclusive

LCR Technology covered under U.S. patent

GenPharm describes high-affinity human IgG monoclonal antibodies

Roche licenses PCR technology to Immuno

Chiron and Behringwerke form vaccine joint venture

Medtronic/InStent merger complete

Medeva acquires French rights to some RPR OTC products

First approval of SmithKline Beecham's ReQuip in U.K.

First demonstration of cellular mechanism of human oral tolerance

Muscarinic receptor ligand selected for further study

TNF research findings

NOS inhibitors from Merck & Co.

Novel 5-lipoxygenase inhibitors described by Pfizer

WAY-126120: Selective PDE IV inhibitor

APC-366 covered under U.S. patent

Torii and Hisamitsu disclose elastase inhibitors

Icos granted U.S. patent for rPAF-AH

Na+/K+-ATPase inhibitors revealed by Sigma-Tau

Endothelin antagonists part of Fujisawa's pipeline

NEP inhibition research findings

Smooth muscle cell proliferation inhibitors described by American Home Products

Teijin's prostaglandin MCP-1/MCAF inhibitors

Bristol-Myers Squibb's Pravachol cleared by FDA for new indication

TxA2 antagonists/TxA2 synthase inhibitors from Fujisawa

NovoSeven hits U.K. market

Selective alpha1A-adrenoceptor antagonists with multiple indications

5alpha-Reductase inhibitors from Kyowa Hakko

Cystistat covered under U.S. patent

Novopharm favored in patent infringement suit with Glaxo Wellcome

Otsuka peptide IL-1 production inhibitors in pipeline

Lamivudine for treatment of hepatitis B covered under U.S. patent

Clinical trials begin for chronic hepatitis C agent, Alferon N Injection

Aldose reductase inhibitors described by Grelan

KGR-1380: A novel glycation inhibitor

New formulation of rhGH from Alkermes and Genentech

U.K. and Canadian approval sought for Alora

RWJ-26819: Non-steroidal progestin agonist from R.W. Johnson

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...